GlassScriptPhysician profile
Jonathan Michael Sardina
NPI 1053629535
$1,612.08
in general payments reported to CMS, 2019-2025
17 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $229 · 2024: $917 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,593 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,593.23 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $298.89 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Shield Therapeutics INC | $203.12 | 2023-2025 | |
| Pfizer INC. | $166.23 | 2023-2025 | |
| Abbvie INC. | $160.41 | 2023-2025 | Vraylar |
| Lilly USA, LLC | $145.72 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $130.45 | 2024-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $115.70 | 2024-2025 | Farxiga, Airsupra |
| Dexcom, INC. | $78.38 | 2023-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $71.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $46.80 | 2024-2025 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.67 | 2024-2025 | Jardiance, Tradjenta |
| Xeris Pharmaceuticals, INC. | $39.74 | 2024 | Keveyis, Gvoke Hypopen |
| Mylan Specialty L.P. | $34.56 | 2023-2024 | Yupelri |
| Boston Scientific Corporation | $23.86 | 2024 | Watchman Flx |
| Optinose US, INC. | $18.13 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $16.10 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $15.92 | 2025 | Gardasil 9, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Sardina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.